Respiratory Panel Flow-Strip: a Point-of-Care Molecular Diagnostic Test
呼吸面板 Flow-Strip:护理点分子诊断测试
基本信息
- 批准号:8314204
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-03-01 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcute respiratory infectionAddressAdenovirusesBacteriaBedside TestingsBiological AssayBordetella pertussisCause of DeathCessation of lifeChildChlamydophila pneumoniaeClinicalCommunicable DiseasesDNADetectionDevicesDiagnosticDiagnostic testsDrug resistanceEvolutionFeasibility StudiesFreeze DryingGenesGenomeGenomicsGoalsGoldHaemophilus influenzaeHealth Care CostsHumanHuman AdenovirusesHuman Coronavirus 229EHuman MetapneumovirusHuman Parainfluenza Virus 1Human respiratory syncytial virusImmunoassayIndividualInfectionInfluenzaInfluenza A virusInfluenza B virusInjection of therapeutic agentLateralLegionella pneumophilaLifeMarketingMeasuresMoldsMolecularMolecular Diagnostic TestingMorbidity - disease rateMycoplasma pneumoniaeOrganismOutcomePara-Influenza Virus Type 1PatientsPhasePlasticsPneumoniaProcessRNAReadinessReverse Transcriptase Polymerase Chain ReactionRhinovirusSARS coronavirusSamplingSensitivity and SpecificitySexually Transmitted DiseasesSpecimenStreptococcusStreptococcus pneumoniaeSwabSystemTechniquesTestingTranslatingTubeVirusWorkbiochipevaluation/testingfluhuman coronavirusimprovedinstrumentationmicroorganismmortalityoperationpandemic diseasepathogenpoint of careprototyperesistant strainrespiratoryrespiratory virusresponsetool
项目摘要
DESCRIPTION (provided by applicant): Acute respiratory infections are the third leading cause of death worldwide, and account for 4.2 million deaths annually; more than 40% are children under five. Conventional techniques are often either too slow (e.g., conventional cultures require 5 to 10 days) or too insensitive (e.g., one study found the sensitivity of a laterl flow immunoassay test for flu to be as low as 10.4%). Despite their insensitivity, the lateral flow
test market for infectious disease grew over 40% in 2009. Because of its sensitivity and specificity, molecular testing are beginning to supplant conventional culture as the gold standard. However, limitations with current molecular tests for identifying multiple respiratory pathogens from a single sample include: high complexity operation, lack of sensitivity, lack of respiratory pathogen coverage, and/or lack of sequence coverage for a given pathogen. Thus, we propose to address these limitations with an automated sample-to-answer point-of- care molecular device that identifies hypervariable genomes across the following panel of respiratory pathogens: influenza A virus, influenza B virus, human respiratory syncytial virus A/B, human adenovirus A/B/C/D/E/F, human coronavirus 229E/NL63/OC43, metapneumovirus, human rhinovirus A/B/C, human bocavirus 1/2/3/4, human parainfluenza virus 1/2/3/4, Haemophilus influenzae, Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, and Bordetella pertussis.
PUBLIC HEALTH RELEVANCE: Acute respiratory infections are the third leading cause of death worldwide, and account for 4.2 million deaths annually; more than 40% are children under five. The pathogens that cause these infections often are highly contagious, and infect susceptible individuals before tests can be commercialized. This project seeks to develop a point-of-care test that identifies a panel of bacteria and viruses, including drug-resistant strain of flu, from a single patient sample. This test could assist in the preparedness for global pandemics because of the ongoing availability of a test that can identify a broad panel of contagious respiratory pathogens. This strategy has the potential to eliminate the burden of having to quickly develop and commercialize single-organism tests in response to an emerging pandemic.
描述(由申请人提供):急性呼吸道感染是全球第三大死亡原因,每年造成420万人死亡;超过40%是五岁以下儿童。常规技术通常要么太慢(例如,常规培养需要5至10天)或太不敏感(例如,一项研究发现流感的侧流免疫测定试验的灵敏度低至10.4%。尽管它们不敏感,
2009年,传染病检测市场增长超过40%。由于其敏感性和特异性,分子检测开始取代传统的培养作为金标准。然而,用于从单个样品鉴定多种呼吸道病原体的当前分子测试的局限性包括:高复杂性操作、缺乏灵敏度、缺乏呼吸道病原体覆盖和/或缺乏给定病原体的序列覆盖。因此,我们建议使用自动化样本到答案的即时分子设备来解决这些限制,该设备可以识别以下呼吸道病原体中的高变基因组:流感A病毒、流感B病毒、人呼吸道合胞病毒A/B、人腺病毒A/B/C/D/E/F、人冠状病毒229 E/NL 63/OC 43、偏肺病毒、人鼻病毒A/B/C、人博卡病毒1/2/3/4、人副流感病毒1/2/3/4、流感嗜血杆菌、肺炎链球菌、肺炎支原体、肺炎衣原体、嗜肺军团菌和百日咳杆菌。
公共卫生相关性:急性呼吸道感染是全球第三大死因,每年造成420万人死亡,其中40%以上是5岁以下儿童。导致这些感染的病原体通常具有高度传染性,并在测试商业化之前感染易感个体。该项目旨在开发一种即时检测方法,从单个患者样本中识别一组细菌和病毒,包括耐药流感菌株。这种测试可以帮助防备全球大流行病,因为目前有一种测试可以识别一系列广泛的传染性呼吸道病原体。这一战略有可能消除为应对新出现的大流行而必须迅速开发和商业化单一微生物检测的负担。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DARRELL P CHANDLER其他文献
DARRELL P CHANDLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DARRELL P CHANDLER', 18)}}的其他基金
Diagnostic MDR- and XDR-TB PCR TruArray
诊断性耐多药结核病和广泛耐药结核病 PCR TruArray
- 批准号:
7921703 - 财政年份:2010
- 资助金额:
$ 30万 - 项目类别:
CELLULAR ARCHITECTURE III: LIGHT HARVESTING COMPLEX II
蜂窝架构 III:光采集复合体 II
- 批准号:
7955618 - 财政年份:2009
- 资助金额:
$ 30万 - 项目类别:
相似海外基金
2022 Biology of Acute Respiratory Infection GRC / GRS
2022 急性呼吸道感染生物学 GRC / GRS
- 批准号:
10388659 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
The Canadian Severe Acute Respiratory Infection, Prospective, Perpetual Observational Study: Informing Clinical Care and the Public Health Response
加拿大严重急性呼吸道感染前瞻性、永久性观察研究:为临床护理和公共卫生应对提供信息
- 批准号:
462643 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Operating Grants
The Canadian Severe Acute Respiratory Infection, Prospective, Perpetual Observational Study: Informing Clinical Care and the Public Health Response
加拿大严重急性呼吸道感染前瞻性、永久性观察研究:为临床护理和公共卫生应对提供信息
- 批准号:
442907 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Operating Grants
2020 Biology of Acute Respiratory Infection Gordon Research Conference and Gordon Research Seminar
2020急性呼吸道感染生物学戈登研究大会暨戈登研究研讨会
- 批准号:
9913675 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
New test for the diagnosis of acute respiratory infection that detects viruses and evaluates host gene expression in a nasal sample
用于诊断急性呼吸道感染的新测试,可检测鼻腔样本中的病毒并评估宿主基因表达
- 批准号:
9809720 - 财政年份:2019
- 资助金额:
$ 30万 - 项目类别:
2016 Biology of Acute Respiratory Infection Gordon Research Conference & Gordon Research Seminar
2016年急性呼吸道感染生物学戈登研究会议
- 批准号:
9121654 - 财政年份:2016
- 资助金额:
$ 30万 - 项目类别:
2014 Biology of Acute Respiratory Infection Gordon Research Conference and Semina
2014年急性呼吸道感染生物学戈登研究会议及研讨会
- 批准号:
8650427 - 财政年份:2014
- 资助金额:
$ 30万 - 项目类别:
Meditation and Exercise for Preventing Acute Respiratory Infection (MEPARI-2)
预防急性呼吸道感染的冥想和运动(MEPARI-2)
- 批准号:
8867144 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
Meditation and Exercise for Preventing Acute Respiratory Infection (MEPARI-2)
预防急性呼吸道感染的冥想和运动(MEPARI-2)
- 批准号:
9098602 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
2012 Biology of Acute Respiratory Infection Gordon Research Conference
2012年急性呼吸道感染生物学戈登研究会议
- 批准号:
8249190 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别: